About Panacea Biotec

Overview 

 

Panacea Biotec Limited is an Indian pharmaceutical and health management company headquartered in New Delhi, India. Established in 1984, the company manufactures and markets pharmaceutical formulations and vaccines to 20+ countries, and offers Contract Research & Manufacturing Services (CRAMS) in procurement, manufacturing, packaging and product development.

 

The company’s product portfolio includes prescription products in cardiovascular management, diabetes, oncology, nephrology & transplant management, osteoporosis management, anti-tubercular, gastro-intestinal care, pain management and paediatrics.

 

Company Highlights (2015-16)

  • Key export markets include USA, Germany, CIS countries, LATAM countries, Africa, Middle East and other Asian countries
  • Niche therapeutic areas in India include Transplantation & Immunology, Nephrology, Oncology, Diabetes, Orthopaedics, Gastroenterology and Pain Management 
  • 5 manufacturing facilities in India
  • 4 R&D Centres in India, with 7% of net turnover invested in R&D during 2015-16
  • The company’s top 3 selling brands featured among the top 500 brands in India
  • Awarded Silver Brand for Glizid-M in Chronic Care Therapy by AWACS AIOCD
  • Received Thomson Reuters Intellectual Property & Science Award for 2015 as “Top 50 Indian Innovators - 2015”
  • Launched India's first indigenously developed brand at one fifth of the innovator's price for treating metastatic Castration Resistant Prostrate Cancer (mCRPC), CABAPAN (Cabazitaxel)
  • Was ranked amongst the top 60 Pharmaceutical Companies in India 
  • (AIOCD-AWACD-MAT-MAR-2016)
  • Leading Brands
    • 4 brands ranked #1 in their respective therapy areas
      (anti-neoplastics and anti-diabetic)
    • 6 brands ranked among India’s top 5 brands in their respective therapeutic areas
      (pain / analgesics, gastro intestinal and varicose therapy)

Panacea Biotec Ltd. is listed both on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

 

Panacea Biotec Limited at-a-glance

 

  • Sales Turnover (31 March, 2016) USD 93.4 million

?619.65 crores

  • Employees (31 March, 2016) ~2,500
  • Markets Served (countries) 20+
  • Manufacturing Facilities 5
  • ANDAs (US FDA) 6

Certifications

  • US FDA
  • WHO-cGMP
  • BfArM Germany 

Source: http://www.panacea-biotec.com

 

History

 

The company has not shared this information

 

Milestones

 

  • 1984: Panacea Drug (P) Ltd. is established

  • 1988: Sets up vaccine production plant in New Delhi (Radicura Pharma)

  • 1989: Sets up a formulations plant in New Delhi

  • 1993: Panacea Biotec Ltd. is formed out of the merger of Radicura Pharma and Panacea Drugs (P) Ltd.

  • 1995:

    • Rolls out a ?180 million IPO (equity shares)

    • Sets up R&D centre in Lalru

  • 1997: Patents first international product

  • 2001: Ties up with a European MNC for R&D

  • 2002:

    • Signs in-licensing agreement to develop and commercialize Anthrax Vaccine with Biotechnology Consortium of India

    • Commissions production plant for Recombinant Vaccines

  • 2004:

    • Partners with Cambridge Bio-stability, UK, for Thermostable

Vaccines

    • Forms JV with Chiron (now Novartis) Vaccines, UK

    • Signs in-licensing agreement with National Institute of

Immunology, New Delhi, for Japanese Encephalitis Candidate

Vaccine

  • 2005: Signs in-licensing agreement for hair growth hormone with National Institute of Health, USA

  • 2006:

    • Receives compliance certificate from WHO cGMP for cutting-edge

formulations facility at Baddi, Himachal Pradesh

    • Collaborates with The Netherlands Vaccine Institute (Netherlands)

Vaccine Institute (NVI)) to manufacture and market finished

Inactivated Polio Vaccine (IPV) along with IPV based combination

vaccines in India and overseas

    • Collaborates to manufacture and market measles vaccine with PT. Bio Farma

    • Starts an R&D Centre in New Delhi

    • Obtains WHO (Pre-Qualification) Certification to supply

recombinant Hepatitis-B Vaccine to UN Agencies

    • Collaborates with National Research Development Corporation

(NRDC) for technology transfer of Foot and Mouth Vaccine

  • 2007:

    • Sets up a vaccine formulation plant in Baddi, Himachal Pradesh

    • Signs Research Agreement to develop new chemical entities for psychiatric disorders (with Punjab University)

  • 2008:

    • Partners to establish multi super-specialty hospital (220 beds) in NCR

    • Obtains WHO prequalification for fully liquid innovative combination

Pentavalent vaccine, EasyFive against five lethal early childhood infectious diseases (DTwP+ Hep B+ Hib)

    • Granted patent from US Patent & Trademark Office for management of haemorrhoids & piles

 

BOARD OF DIRECTORS

 

  • Chairman -  Mr. Soshil Kumar Jain
  • Managing Director - Mr. Ravinder Jain
  • Joint Managing Director - Dr. Rajesh Jain
  • Joint Managing Director - Mr. Sandeep Jain
  • Director - Operations & Projects - Mr. Sumit Jain
  • Director – Sales & Marketing - Mr. Ankesh Jain
  • Non-Executive Directors - Mr. RL Narasimhan, Mr. NN Khamitkar, Mr. KM Lal, Mr. OP Kelkar, Mrs. Manjula Upadhyay, Mr. Mukul Gupta

 

CONTACTS


 

CORPORATE OFFICE

B-1 Extn. / G-3

Mohan Co-operative Industrial Estate

Mathura Road

New Delhi -110044

India

 

Website: http://www.panacea-biotec.com/

Tel: +91 11-26945270, 26974500, 41678000

Fax: +91-11-41679081, 26940199

 

 

 

as per AIOCD AWACS (MAT March 2016) data



Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...